Application of FibroScan technique combined with serum osteocalcin in postmenopausal women with nonalcoholic fatty liver disease

Abstract

Abstract: Objective The purpose of this study was to evaluate the degree of hepatic steatosis in postmenopausal women with nonalcoholic fatty liver disease (NAFLD) by measuring hepatic fat decay by FibroScan and serum osteocalcin (OC). Methods From Jan. 2016 to Mar. 20, 2016 postmenopausal women with NAFLD were admitted and their age was (45.0±8.2) years old. NAFLD was based on the guidelines for diagnosis and treatment of non-alcoholic Fatty liver Disease (revised in 2010). The Spearman correlation coefficient is used to evaluate the correlation, the ROC curve is drawn to evaluate the diagnostic efficiency, and the diagnostic cutoff point is determined when the Jordan index reaches its maximum. Results Among the postmenopausal women with NAFLD, there were 27 cases of stage S0, 46 cases of stage S1, 35 cases of stage S2 and 18 cases of stage S3. The CAP values of FibroScan in each stage were (208.4±32.6) dB/m, (221.5±40.4) dB/m, (265.4±37.1) dB/m, (311.5±50.4) dB/m, respectively, and the serum OC values in each stage were (23.1±2.4) ng/ml, (21.8±2.9) ng/ml, (20.4±1.8) ng/ml, (18.2±2.0) ng/ml, respectively. Correlation analysis showed that the stage of hepatic steatosis in postmenopausal women with NAFLD was positively correlated with CAP (r=0.38, P<0.05), but negatively correlated with serum OC (r=0.27, P<0.05). The AUROC, cut-off point, sensitivity and specificity of serum OC in the diagnosis of hepatic steatosis in postmenopausal women with NAFLD were 0.84,20.9 ng/mL, 84.8% and 83.6%, respectively. AUROC, cut-off point, sensitivity and specificity were 0.85, 255.8dB/m, 76.0% and 90.4%, respectively. After combined diagnosis, the AUROC, sensitivity and specificity were 0.90,88.2% and 92.6%, respectively. Conclusion The measurement of serum OC and FibroScan is of high value in the diagnosis of hepatic steatosis in postmenopausal women with NAFLD, and the diagnostic efficiency is further improved after the combined diagnosis of CAP and CAP.

Key words: Nonalcoholic fatty liver disease, Osteocalcin, Transient elastography, FibroScan, Liver fat attenuation value

ZHANG Jin, ZHANG Hai. Application of FibroScan technique combined with serum osteocalcin in postmenopausal women with nonalcoholic fatty liver disease[J]. Chinese Hepatolgy, 2020, 25(9): 975-977.

References

[1] Jiang DX, Zhang JB, Li MT, et al. Prolyl endopeptidase gene disruption attenuates high fat diet-induced nonalcoholic fatty liver disease in mice by improving hepatic steatosis and inflammation. Ann Transl Med, 2020, 8:218.
[2] Xu L, Mi YQ. Characteristics, diagnostic and therapeutic strategies for chronic hepatitis B combined with non-alcoholic fatty liver disease. Zhonghua Gan Zang Bing Za Zhi, 2020, 28:198-202.
[3] Chen HT, Zhou YJ. Diagnosis and therapeutic strategies for non-alcoholic fatty liver disease in children. Zhonghua Gan Zang Bing Za Zhi, 2020, 28:208-212.
[4] Movahed A, Larijani B, Nabipour I, et al. Reduced serum osteocalcin concentrations are associated with type 2 diabetes mellitus and the metabolic syndrome components in postmenopausal women: the crosstalk between bone and energy metabolism. J Bone Miner Metab, 2012, 30: 683-691.
[5] Oosterwerff MM, van Schoor NM, Lips P, et al. Osteocalcin as a predictor of the metabolic syndrome in older persons: a populationbased study. Clin Endocrinol(Oxf), 2013, 78: 242-247.
[6] Gupte AA, Sabek OM, Fraga D, et al. Osteocalcin protects against nonalcoholic steatohepatitis in a mouse model of metabolic syndrome. Endocrinology, 2014, 155: 4697-705.
[7] Liu JJ, Chen YY, Mo ZN, et al. Relationship between serum osteocalcin levels and non-alcoholic fatty liver disease in adult males, South China. Int J Mol Sci, 2013, 14: 19782-19791.
[8] Zhou M, Ma X, Li H, et al. Serum osteocalcin concentrations in relation to glucose and lipid metabolism in Chinese individuals. Eur J Endocrinol, 2009, 161: 723-729.
[9] 王荣琦, 任伟光, 赵素贤, 等. 瞬时弹性成像技术与多参数模型评估慢性肝病肝纤维化程度的临床研究. 中华肝脏病杂志, 2015, 23:265-269.
[10] Sripongpun P, Tangkijvanich P, Chotiyaputta W, et al. Evaluation of aspartate aminotransferase to platelet ratio index and fibrosis 4 scores for hepatic fibrosis assessment compared with transient elastography in chronic hepatitis C patients. JGH Open, 2019, 4:69-74.
[11] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版). 胃肠病学和肝病学杂志, 2010, 19:483-487.
[12] Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med, 2010, 363: 1341-1350.
[13] Gao X, Fan JG. Diagnosis and management of non-alcoholic fatty 1iver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology. J Diabetes, 2013, 5: 406-415.
[14] Yang R, Ma X, Pan X, et al. Serum osteocalcin levels in relation to metabolic syndrome in Chinese postmenopausal women. Menopause, 2013, 20: 548-553.
[15] Díaz-López A, Bulló M, Juanola-Falgarona M, et al. Reduced serum concentrations of carboxylated and undercarboxylated osteocalcin are associated with risk of developing type 2 diabetes mellitus in a high cardiovascular risk population: a nested case-control study. J Clin Endocrinol Metab, 2013, 98: 4524-4531.
[16] Sarkar PD, Choudhury AB. Relationships between serum osteocalcin levels versus blood glucose, insulin resistance and markers of systemic inflammation in central Indian type 2 diabetic patients. Eur Rev Med Pharmacol Sci, 2013, 17: 1631-1635.
[17] Sinn DH, Gwak GY, Rhee SY, et al. Association between serum osteocalcin levels and non-alcoholic fatty liver disease in women. Digestion, 2015, 91: 150-157.
[18] Luo YQ, Ma XJ, Hao YP, et al. Inverse relationship between serum osteocalcin levels and nonalcoholic fatty liver disease in postmenopausal Chinese women with normal blood glucose levels. Acta Pharmacol Sin, 2015, 36:1497-1502.